ASCO 2023
ASCO 2023
Advertisement
Oncology BrothersOncology Brothers | June 5, 2023
The Oncology Brothers were live at ASCO 2023 to discuss findings from the TROPiCS-02 study.
View More
Oncology BrothersOncology Brothers | June 5, 2023
The Oncology Brothers discuss findings from the phase 3 ADAURA trial.
Dr. Patrick FordeASCO 2023 | June 5, 2023
Dr. Patrick Forde spoke with DocWire News at ASCO 2023 about updated data from the CheckMate 816 trial.
Rob DillardASCO 2023 | June 3, 2023
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Rob DillardASCO 2023 | June 3, 2023
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
Rob DillardASCO 2023 | June 3, 2023
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Rob DillardASCO 2023 | June 3, 2023
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
Rob DillardASCO 2023 | May 31, 2023
US veterans who were exposed to Agent Orange have an increased risk of myeloproliferative neoplasms.
Rob DillardASCO 2023 | May 31, 2023
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
Rob DillardASCO 2023 | May 31, 2023
The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis.
Rob DillardASCO 2023 | May 31, 2023
Patients admitted for atrial fibrillation who have myeloproliferative neoplasms have an increased risk of bleeding.
Rob DillardASCO 2023 | May 26, 2023
Extending colorectal cancer screening to older populations using stool testing results in more life years gained.
Rob DillardASCO 2023 | May 25, 2023
People with a history of skin cancer lack sufficient knowledge on photoprotection, study finds.
Advertisement
Advertisement
Advertisement
Latest News

June 5, 2023